The clinical trial testing Sarepta Therapeutics, Inc.’s gene therapy candidate in Duchenne muscular dystrophy enrolled remarkably faster than the company’s studies looking at three drugs that treat the rare disease, a likely function of its potential and a concern for the others’ futures.
SRP-9001 (delandistrogene moxeparvovec) is under priority review at the US Food and Drug Administration for accelerated approval. The EMBARK trial...